Media Releases - 11 August 2023
Statement on Fiasp insulin supply
Access to Fiasp insulin through the pharmaceutical benefits scheme (PBS) is due to end October 1, 2023. The fast acting insulin product used by people living with Type 1 diabetes has been under supply only arrangements since April this year, after Novo Nordisk opted to remove Fiasp from the PBS for commercial reasons.
During the supply only period, people have been able to refill their current prescription and repeat scripts at a pharmacy.
After October 1, Fiasp will only be available via private script at a higher cost compared to the subsidised price.
Diabetes Victoria is working closely with Diabetes Australia, the Therapeutic Goods Administration and industry to ensure Australians living with Type 1 diabetes will continue to have access to fast acting insulin.
We encourage anyone who has concerns to raise their voice via Diabetes Australia’s Spark Change platform, write to your local MP and federal Health Minister the Hon Mark Butler MP and consider making a submission to the parliamentary inquiry into diabetes.
For advice about your own diabetes management, speak with a member of your diabetes healthcare team or call the Diabetes Victoria Help Centre on 1300 437 386.
Media enquiries:
Britt Denton | bdenton@diabetesvic.org.au | 0488 133 316
Diabetes Victoria
Wurundjeri Woi-wurrung Country
comms@diabetesvic.org.au
